A prospective, randomized trial of silver containing hydrofiber dressing versus 1% silver sulfadiazine for the treatment of partial thickness burns.
Silver sulfadiazine has been used as a topical burn wound treatment for many years. Pain associated with dressing changes is a common problem in burn wounds. Aquacel Ag, a hydrofiber dressing coated with ionic silver has been reported to reduce burn wound infection and promote antimicrobial activity. The purpose of this study was to show the benefits of Aquacel Ag for the treatment of partial thickness burns. This prospective randomized study was conducted in 70 patients who had partial thickness burns less than 15% of total body surface area and were treated at Siriraj outpatient burn clinic during December 2006-February 2008. Patients were divided into two groups: Aquacel Ag-treated group with dressing changes every 3 days (35 patients) and 1% silver sulfadiazine-treated group, with daily dressing changes (35 patients). There was no difference in demographic data including age, gender, burn percentage between groups. Time-to-wound healing pain score during dressing change and cost of treatment were compared between both groups. Time-to-wound closure was significantly shorter in the Aquacel Ag-treated group (10 +/- 3 versus 13.7 +/- 4 days, P < 0.02) as well as pain scores at days 1, 3 and 7 (4.1 +/- 2.1, 2.1 +/- 1.8, 0.9 +/- 1.4 versus 6.1 +/- 2.3, 5.2 +/- 2.1, 3.3 +/- 1.9, respectively, P < 0.02). Total cost of treatment was 52 +/- 29 US dollars for the Aquacel Ag-treated group versus 93 +/- 36 US dollars for the silver sulfadiazine-treated group. This study showed that Aquacel Ag increased time to healing, decreased pain symptoms and increased patient convenience because of limiting the frequency of replacement of the dressing at lower total cost. This study confirms the efficacy of Aquacel Ag for the treatment of partial thickness burns at an outpatient clinic.
Burn Unit, Trauma Division, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. pmuangman@yahoo.com
Pornprom
P
Muangman
Chanin
C
Pundee
Supaporn
S
Opasanon
Saipin
S
Muangman
D000328:Adult; D000553:Ambulatory Care / Q000191:economics; D000891:Anti-Infective Agents, Local / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D001830:Body Surface Area; D002056:Burns / Q000150:complications / Q000628:therapy*; D002266:Carboxymethylcellulose Sodium / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005260:Female; D017721:Hospital Costs / Q000706:statistics & numerical data; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology; D011446:Prospective Studies; D012837:Silver Sulfadiazine / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D017592:Skin Care / Q000009:adverse effects / Q000191:economics / Q000379:methods; D013785:Thailand; D013997:Time Factors; D014195:Travel / Q000191:economics; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects
D000891:Anti-Infective Agents, Local; D002266:Carboxymethylcellulose Sodium; D012837:Silver Sulfadiazine